glp 1 drugs kidney disease GLP-1 Receptor Agonists in the Treatment of Patients with Type 2 Diabetes and Chronic FDA clears use of Ozempic
Description
Based on current timelines, FDA submission could occur in 2026-2027 with potential approval in 2027-2028
Despite the ability of GLP-1s to produce significant weight reduction and related health benefits, challenges such as GI side effects, risk of nutrient inadequacies, loss of muscle and bone mass, high costs, frequent discontinuation, and weight regain limit, the use of these drugs for long-term success in individuals and populations
Notably, a large portion of use is do-it-yourself regimen change
Retrieved from Gorgojo-Martnez, J
Mol Metab, 2024
